Israeli biotechnology company BioBlast is developing and testing Cabaletta, designed to counteract abnormal clumping of cellular proteins in oculopharnyngeal muscular dystrophy (OPMD)
New content is being added every day. Please check back again.
Muscular Dystrophy Association — USA National Office222 S. Riverside Plaza, Suite 1500Chicago, IL 60606(800) 572-1717
©2015, Muscular Dystrophy Association Inc. All rights reserved.